Cargando…
Current modalities of sickle cell disease management
Sickle cell disease (SCD) affects nearly 100,000 people in the United States of America and the sickle gene is present in approximately 8% of black Americans. Among Africans, the prevalence of sickle cell trait (heterozygosity) is as high as 30%. While SCD occurs among varying racial and ethnic grou...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974986/ https://www.ncbi.nlm.nih.gov/pubmed/35400022 http://dx.doi.org/10.1097/BS9.0000000000000056 |
_version_ | 1784680315972747264 |
---|---|
author | Sanyaolu, Adekunle Agiri, Ejoke Bertram, Carl Brookes, Latasha Choudhury, Jesy Datt, Dorina Ibrahim, Amira Maciejko, Anna Mansfield, Anna Nkrumah, Jasmine Williams, Martina |
author_facet | Sanyaolu, Adekunle Agiri, Ejoke Bertram, Carl Brookes, Latasha Choudhury, Jesy Datt, Dorina Ibrahim, Amira Maciejko, Anna Mansfield, Anna Nkrumah, Jasmine Williams, Martina |
author_sort | Sanyaolu, Adekunle |
collection | PubMed |
description | Sickle cell disease (SCD) affects nearly 100,000 people in the United States of America and the sickle gene is present in approximately 8% of black Americans. Among Africans, the prevalence of sickle cell trait (heterozygosity) is as high as 30%. While SCD occurs among varying racial and ethnic groups, it is more commonly prevalent in individuals of African or African-American descent. This inherited blood disorder causes varying symptoms and complications among affected children and adults and early diagnosis and treatment are essential to help reduce mortality rates. Because there is no cure for SCD, management is vital to survival. Hence, there are different approaches in use to aid those living with SCD; thus, this paper provides insight into the current methods that are implemented in the management and maintenance of this disease. |
format | Online Article Text |
id | pubmed-8974986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-89749862022-04-07 Current modalities of sickle cell disease management Sanyaolu, Adekunle Agiri, Ejoke Bertram, Carl Brookes, Latasha Choudhury, Jesy Datt, Dorina Ibrahim, Amira Maciejko, Anna Mansfield, Anna Nkrumah, Jasmine Williams, Martina Blood Sci Review Article Sickle cell disease (SCD) affects nearly 100,000 people in the United States of America and the sickle gene is present in approximately 8% of black Americans. Among Africans, the prevalence of sickle cell trait (heterozygosity) is as high as 30%. While SCD occurs among varying racial and ethnic groups, it is more commonly prevalent in individuals of African or African-American descent. This inherited blood disorder causes varying symptoms and complications among affected children and adults and early diagnosis and treatment are essential to help reduce mortality rates. Because there is no cure for SCD, management is vital to survival. Hence, there are different approaches in use to aid those living with SCD; thus, this paper provides insight into the current methods that are implemented in the management and maintenance of this disease. Lippincott Williams & Wilkins 2020-08-27 /pmc/articles/PMC8974986/ /pubmed/35400022 http://dx.doi.org/10.1097/BS9.0000000000000056 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Association for Blood Sciences. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Review Article Sanyaolu, Adekunle Agiri, Ejoke Bertram, Carl Brookes, Latasha Choudhury, Jesy Datt, Dorina Ibrahim, Amira Maciejko, Anna Mansfield, Anna Nkrumah, Jasmine Williams, Martina Current modalities of sickle cell disease management |
title | Current modalities of sickle cell disease management |
title_full | Current modalities of sickle cell disease management |
title_fullStr | Current modalities of sickle cell disease management |
title_full_unstemmed | Current modalities of sickle cell disease management |
title_short | Current modalities of sickle cell disease management |
title_sort | current modalities of sickle cell disease management |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974986/ https://www.ncbi.nlm.nih.gov/pubmed/35400022 http://dx.doi.org/10.1097/BS9.0000000000000056 |
work_keys_str_mv | AT sanyaoluadekunle currentmodalitiesofsicklecelldiseasemanagement AT agiriejoke currentmodalitiesofsicklecelldiseasemanagement AT bertramcarl currentmodalitiesofsicklecelldiseasemanagement AT brookeslatasha currentmodalitiesofsicklecelldiseasemanagement AT choudhuryjesy currentmodalitiesofsicklecelldiseasemanagement AT dattdorina currentmodalitiesofsicklecelldiseasemanagement AT ibrahimamira currentmodalitiesofsicklecelldiseasemanagement AT maciejkoanna currentmodalitiesofsicklecelldiseasemanagement AT mansfieldanna currentmodalitiesofsicklecelldiseasemanagement AT nkrumahjasmine currentmodalitiesofsicklecelldiseasemanagement AT williamsmartina currentmodalitiesofsicklecelldiseasemanagement |